Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Equities research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a research note issued on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of $0.08 per share for the quarter, down from their previous estimate of $0.14. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.29 EPS, Q1 2027 earnings at $0.18 EPS, Q2 2027 earnings at $0.26 EPS and FY2027 earnings at $1.20 EPS.
Fennec Pharmaceuticals Stock Performance
TSE FRX opened at C$17.10 on Thursday. The business has a 50 day simple moving average of C$15.55 and a 200 day simple moving average of C$12.70. Fennec Pharmaceuticals has a 52-week low of C$7.59 and a 52-week high of C$17.64. The stock has a market cap of C$599.65 million, a price-to-earnings ratio of -142.50 and a beta of 3.72.
Hedge Funds Weigh In On Fennec Pharmaceuticals
A hedge fund recently bought a new position in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. bought a new position in shares of Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 105,000 shares of the biopharmaceutical company's stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals at the end of the most recent quarter. Institutional investors own 15.40% of the company's stock.
Insider Activity at Fennec Pharmaceuticals
In other news, insider Robert Christopher Andrade sold 106,844 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of C$16.63, for a total transaction of C$1,776,815.72. Following the completion of the sale, the insider owned 217,675 shares of the company's stock, valued at C$3,619,935.25. This represents a 32.92% decrease in their ownership of the stock. Also, insider Pierre Sayad sold 12,000 shares of the firm's stock in a transaction on Friday, September 4th. The stock was sold at an average price of C$17.18, for a total transaction of C$206,160.00. Following the sale, the insider owned 9,519 shares in the company, valued at approximately C$163,536.42. The trade was a 55.76% decrease in their ownership of the stock. 16.20% of the stock is owned by corporate insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
